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Oxidative stressStatins are standard therapy for the treatment of lipid disorders, and the ﬁeld of redox biology accepts that
statins have antioxidant properties. Our aim in this report was to consider the pleiotropic effects of atorva-
statin, pravastatin and simvastatin administered prior to endotoxin-induced acute lung injury. Male mice
were divided into 5 groups and intraperitoneally injected with LPS (10 mg/kg), LPS plus atorvastatin
(10 mg/kg/day; A + LPS group), LPS plus pravastatin (5 mg/kg/day; P + LPS group) or LPS plus simvastatin
(20 mg/kg/day; S + LPS group). The control group received saline. All mice were sacriﬁced one day later.
There were fewer leukocytes in the P + LPS and S + LPS groups than in the LPS group. MCP-1 cytokine levels
were lower in the P + LPS group, while IL-6 levels were lower in the P + LPS and S + LPS groups. TNF-α was
lower in all statin-treated groups. Levels of redox markers (superoxide dismutase and catalase) were lower in
the A + LPS group (p b 0.01). The extent of lipid peroxidation (malondialdehyde and hydroperoxides) was re-
duced in all statin-treated groups (p b 0.05). Myeloperoxidase was lower in the P + LPS group (p b 0.01).
Elastance levels were signiﬁcantly greater in the LPS group compared to the statin groups. Our results suggest
that atorvastatin and pravastatin but not simvastatin exhibit anti-inﬂammatory and antioxidant activity in
endotoxin-induced acute lung injury.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Acute lung injury and its most severe manifestation, acute respira-
tory distress syndrome, is a clinical syndrome deﬁned by acute respi-
ratory hypoxemia, bilateral pulmonary inﬁltrates consistent with
edema and normal cardiac ﬁlling pressure [4]. Acute lung injury and
acute respiratory distress syndrome are characterized by the leakage
of a ﬂuid rich in protein within the interstitium and alveolar space, an
extensive release of cytokines and neutrophil migration [5]. A com-
mon cause of acute lung injury is systemic inﬂammatory response syn-
drome. Systemic inﬂammatory response syndrome is an imbalance of
the immune response leading to the systemic release of proinﬂammatory
cytokines, chemokines and vasoactive amines [6]. Lipopolysaccharide
(LPS) has been implicated as an important inducer of lung injury andIntegrativa and LABCOM - ICB/
dão, Rio de Janeiro, R.J. CEP
rights reserved.endotoxemia and is therefore used to induce acute lung injury in animal
models [7,8]. The lungs are particularly vulnerable to inﬂammatory
lesions because mediators are released into the circulation, and lungs
receive the entire cardiac output. The accumulation of activated neutro-
phils in the lung is an initial step in the pulmonary inﬂammation that
leads to acute lung injury and histological damage [9,10]. Neutrophils
mediate lung injury by several mechanisms, including the release of
reactive oxygen and nitrogen species, the production of cytokines and
growth factors that can amplify the inﬂammatory response and the
release of proteolytic enzymes [11,12].
Statins, which are inhibitors of the enzyme 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, are a class of drugs
used to lower cholesterol levels in blood [13]. Recent reviews have iden-
tiﬁed pleiotropic properties of statins that go beyond their known
lipid-lowering abilities, such as anti-inﬂammatory [14,15] and antioxi-
dant [16,17] activities. It is speculated that the antioxidant effects of
statins relate to their ability to inhibit the isoprenoid compounds pro-
duced by the mevalonate pathway and their ability to inhibit the activa-
tion of nicotinamide adenine dinucleotide phosphate [18]. In this report,
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astatin and simvastatin against lung oxidative stimulation caused by LPS.
Themethod of choice in this studywas i.p. administration of LPS to create
a model of secondary acute lung injury, where the stimulus originated
outside of the lung and affected this organ by a systemic route. In addition
to redox markers, we analyzed inﬂammation and pulmonary function.
2. Materials and methods
2.1. Animals
Male C57BL/6 mice, 8 to 10 weeks old, were bred and maintained
under standard conditions in the animal facility of the Institute of Bio-
medical Science, Federal University of Rio de Janeiro (Rio de Janeiro,
Brazil). All of the procedures were in accordance with international
guidelines and Brazilian law (the “Arouca” Law) for the use of animals
(Law 11,794 from 10/08/2008), and this study received prior approv-
al from the animal ethics committee of the Federal University of Rio
de Janeiro (DFBCICB046). During the experiment, the animals were
maintained under controlled temperature and humidity (21 ± 2 °C,
50 ± 10%, respectively) and were subjected to 12 h light/dark cycles.
During the experimental procedures, the animals received standard
chow and water ad libitum. This experimental design was repeated
twice (20 mice per group).
2.2. Experimental design
All biochemical reagents were purchased from Sigma (Saint Louis,
MO, USA) unless otherwise speciﬁed. Mice received atorvastatin
(10 mg/kg/day i.p.; [19]), pravastatin (5 mg/kg/day i.p.; [20]), simva-
statin (20 mg/kg/day i.p.; [21]) or saline (i.p.) for three days. On the
third day, mice received LPS (10 mg/kg i.p.). The control group re-
ceived saline (i.p.). These doses were sufﬁcient to fully inhibit HMG
Co-A reductase according to cited references. One day after LPS or sa-
line injection, the mice were killed. Mice were randomly selected for
biochemical (n = 10 per group) or histological (n = 5 per group)
analyses. This experimental design was repeated for pulmonary
mechanics (n = 5 each group, see Section 2.8). The groups were
Control, LPS, A + LPS (atorvastatin), P + LPS (pravastatin) and
S + LPS (simvastatin). A previous experiment (n = 5 per group)
was performed with only statins and saline (i.p.), and no histological
changes were observed (data not shown). Additionally, serum ala-
nine aminotransferase or glutamic pyruvic transaminase activity
was determined using standard spectrophotometric procedures
according to the manufacturer’s protocol (Katal Biotechnology, Belo
Horizonte, Minas Gerais, Brazil), as a control for liver toxicity follow-
ing statin treatment (Fig. 1).Fig. 1. Serum glutamic pyruvic transaminase (GPT) activity as a control for liver toxic-
ity following statin treatment. Data are the means ± SEM (n = 5 for each group).2.3. Bronchoalveolar lavage
The lung air spaces were washed three times with buffered saline
solution (500 μL) for a ﬁnal bronchoalveolar lavage (BAL) ﬂuid vol-
ume of 1.2–1.5 mL. The collected BAL ﬂuid was stored on ice. The
total number of cells in the BAL ﬂuid was determined using a
Neubauer chamber. After BAL, the lungs (n = 10 per group) were re-
moved immediately, homogenized on ice with 10% (w/v) 0.1 M po-
tassium phosphate buffer (pH 7.4) using a tissue homogenizer
(Nova técnica homogenizer model NT136, Campinas, São Paulo,
Brazil) and centrifuged at 800 g for 5 min. The supernatants were
stored at−20 °C for biochemical analysis. The protein concentrations
in the lung homogenate samples were determined by the Bradford
method [22].
2.4. Histopathology
Twenty-four hours after LPS administration, a group of mice (n = 5
per group)was killed. After amidline thoracotomy, the tracheawas can-
nulated, and the lungswereﬁxed by the instillation of 0.5 mLof buffered
formalin (10%) at a pressure of 18-22 cmH2O for 1–2 min. The trachea
was then ligated, and the lungs were immersed in ﬁxative solution for
48 h. The organs were embedded in parafﬁn, sliced (5 μm) and stained
with H&E. Polymorphonuclear (PMN) and mononuclear (MN) cells in
alveoli were counted by morphometry at 1000× magniﬁcation across
10 random non-coincident microscopic ﬁelds in two sections per ani-
mal. Acute lung injury was scored in ten ﬁelds from non-identiﬁed sec-
tions of each group according to the following four criteria: alveolar
congestion, hemorrhage, the inﬁltration of leukocytes in lung tissue,
and the thickness of the alveolar wall/hyaline membrane formation
[1]. Each criterion was graded according to a 5-point scale: 0, minimal
(little) damage; 1, mild damage; 2, moderate damage; 3, severe dam-
age; and 4, maximal damage. Two investigators performed all of the
measurements by counting blinded sections.
2.5. Redox markers
Superoxide dismutase (SOD) activity was assayed by measuring the
inhibition of adrenaline auto-oxidation by absorbance at 480 nm [23].
Catalase (CAT) activitywasmeasured by the rate of decrease in hydrogen
peroxide concentration at 240 nm [24]. As an index of lipid peroxidation,
we used the thiobarbituric acid-reactive substances (TBARS) method for
analyzing malondialdehyde products during an acid-heating reaction, as
previously described by Draper and co-workers [25]. Brieﬂy, samples
from lung homogenates were mixed with 1 mL of 10% trichloroacetic
acid and 1 mL of 0.67% thiobarbituric acid; the sampleswere then heated
in a boiling water bath for 30 min. TBARS levels were determined by ab-
sorbance at 532 nm and expressed as malondialdehyde equivalents
(nmol/mg protein). Lipid hydroperoxide content was assayed with
xylenol orange [26]. Brieﬂy, aliquots of 10–25 μL of the homogenates
were incubated at room temperature for 30 min in amedium containing
0.25 mM FeSO4, 25 mM H2SO4, and 0.1 mM xylenol orange. Blanks
contained all components without supernatant. The ﬁnal sample volume
was 1.5 mL. After incubation, the absorbance at 580 nm was measured.
Carbonyl groups of proteins were determined as previously described
[27]. The tissue samples were mixed with 0.25 mL of 40% trichloroacetic
acid (TCA) (ﬁnal TCA concentration 20%) and centrifuged (5000 g, 5 min,
20 °C). The protein carbonyl content was measured in the resulting
pellets by reaction with 10 mM 2,4-dinitrophenylhydrazine, leading to
the formation of dinitrophenylhydrazones. Myeloperoxidase activity
was measured using hydrogen peroxide, HTAB, and TMB. Initially,
100 μL of each BAL sample was centrifuged with 900 μL of HTAB at
14,000 g for 15 min. The supernatant (75 μL) was incubated with 5 μL
of TMB for 5 min at 37 °C. The mixture was then incubated with 50 μL
of hydrogen peroxide for 10 min at 37 °C, after which 125 μL of sodium
acetate buffer was added. The reaction absorbance was measured at
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ples was determined using a standard curve established using puriﬁed
MPO. Nitrite, a byproduct of NO metabolism, was measured using the
Griess reaction [29]. BAL samples were reacted with 50 μL of 1% sulfanil-
amide solution for 10 min and mixed with 50 μL of 0.1% naphthyl
ethylenediamine solution. The formation of the stable azo compound
with a purple color wasmeasured spectrophotometrically by absorbance
at 540 nm. The method was standardized with known concentrations of
nitrite. Lactate dehydrogenase (LDH) activity in BAL was determined by
monitoring the LDH-catalyzed oxidation of pyruvate coupled with the
reduction of NAD using a commercial kit from Katal Biotechnology and
following the manufacturer’s instructions.2.6. ELISA
Samples of BAL from mice were used for the quantiﬁcation of
MCP-1, IL-6 and TNF-α, which were measured using ELISA kits
(R&D, Minneapolis, MN, USA).2.7. RNA extraction and quantitative real-time PCR
Lung tissue fragments were collected, snap frozen, and stored at
−80 °C in RNAlater (Qiagen, Valencia, CA, USA). Total RNA was iso-
lated using the RNeasy tissue kit (Qiagen). Single-stranded cDNA
was synthesized using the High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA, USA) according to the manufacturer's
protocol. Quantitative real-time PCR was performed using a 7300
real-time PCR System (Applied Biosystems), and the threshold cycle
numbers were determined using the RQ Study Software (Applied
Biosystems). The reactions were performed in triplicate, and the
threshold cycle numbers were averaged. The 50 μL reaction mixture
was prepared as follows: 25 μL of Platinum SYBR Green Quantitative
PCR SuperMix-UDG (Invitrogen Life Technologies, Alameda, CA,
USA), 10 μmol/L of each primer (Table 1) and 10 μL of cDNA
(100 ng). The reaction was performed with a preliminary uracil–
DNA glycosylase treatment for 2 min at 50 °C and a denaturation
step for 2 min at 95 °C, followed by 45 cycles of denaturation at
95 °C for 15 s, annealing for 15 s, and primer extension at 72 °C for
15 s. This process was followed by melting point analysis of the
double-stranded amplicons, consisting of 40 cycles of 1 °C decre-
ments (15 s each) from 95 °C. The ﬁrst derivative of this plot, dF/dT,
is the rate of change of ﬂuorescence in the reaction, and a signiﬁcant
change in ﬂuorescence accompanies the melting curve of the double-
stranded PCR products. A plot of –dF/dT vs. temperature displays
these changes as distinct peaks. Thus, SOD, CAT, MCP-1 and IL-6
expression were examined and normalized to a constitutive gene
(HPRT-1), and the relative fold induction was calculated according
to the formula 2(-ΔΔCt) [30].Table 1
The primers used in quantitative real-time PCR.
Gene Primer Sequence (5’→3’)
SOD Sense TCAATGGTGGGGGACATATT
Antisense GCTTGATAGCCTCCAGCAAC
CAT Sense CCTCGTTCAGGATGTGGTTT
Antisense TCTGGTGATATCGTGGGTGA
MCP-1 Sense ATTCTCCACACCCTGTTTCG
Antisense GATTCCTGGAAGGTGGTCAA
IL-6 Sense CCGGAGAGGAGACTTCACAG
Antisense TCCACGATTTCCCAGAGAAC
HRPT-1 Sense GCTACAGCTTCACCACCACA
Antisense TCTCCAGGGAGGAAGAGGAT
SOD, superoxide dismutase; CAT, catalase; MCP-1, monocyte chemotactic protein-1;
IL-6, interleukin 6; HRPT-1 — hypoxanthine phosphoribosyl-transferase 1.2.8. Pulmonary mechanics
Mice were sedated with diazepam (1 mg, i.p.), anesthetized with
pentobarbital sodium (20 mg/kg BW, i.p.), tracheotomized, and a snug-
ly ﬁtting cannula (0.8 mm i.d.) was introduced into the trachea. The an-
imals were then paralyzed with pancuronium bromide (0.1 mg/kg, i.v.)
and mechanically ventilated with a constant-ﬂow ventilator (Samay
VR15, Universidad de la Republica, Montevideo, Uruguay) with a respi-
ratory frequency of 100 breaths/min, tidal volume of 0.2 mL, ﬂow of
1 mL/s, and positive end-expiratory pressure of 2 cmH2O. The anterior
chest wall was then surgically removed.
A pneumotachograph (15 mm i.d., length 4.2 cm, distance be-
tween side ports = 2.1 cm) [31] was connected to the tracheal can-
nula for the measurements of airﬂow (V′). Lung volume (VT) was
measured by ﬂow signal integration. The pressure gradient across
the pneumotachograph was determined using a Valydine MP45-2
differential pressure transducer (Engineering Corp., Northridge, CA,
USA). The ﬂow resistance of the equipment (Req), tracheal cannula
included, was constant up to ﬂow rates of 26 mL/s and was equal to
0.12 cmH2O mL−1 s. Equipment resistive pressure (=Req · V′) was
subtracted from pulmonary resistive pressure so that the results
represent intrinsic values. Tracheal pressure was measured with a
Validyne MP-45 differential pressure transducer (Engineering Corp.
Northridge, CA, USA). All signals were conditioned and ampliﬁed in
a Beckman type R Dynograph (Schiller Park, IL, USA). Flow and pres-
sure signals were passed through 8-pole Bessel low-pass ﬁlters
(902LPF, Frequency Devices, Haverhill, MA, USA) with the corner
requency set at 100 Hz, sampled at 200 Hz with a 12-bit analog-to-
digital converter (DT2801A, Data Translation, Marlboro, MA, USA),
and stored on a microcomputer. All data were collected using LABDAT
software (RHT-InfoData Inc., Montreal, QC, Canada).
Lung resistive (ΔP1) and viscoelastic/inhomogeneous (ΔP2) pres-
sures, total resistive pressure drop (ΔPtot = ΔP1 + ΔP2), static
elastance (Est), and viscoelastic component of elastance (ΔE) were
measured by the end-inﬂation occlusion method [32,33]. Brieﬂy,
after end-inspiratory occlusion, there is an initial rapid drop in
transpulmonary pressure (ΔP1) from the pre-occlusion value down
to an inﬂection point (Pi), followed by a slow pressure decay (ΔP2)
until a plateau is reached. This plateau corresponds to the elastic
recoil pressure of the lung (Pel). ΔP1 selectively reﬂects airway resis-
tance in normal animals and humans and ΔP2 reﬂects stress relaxa-
tion, or viscoelastic properties of the lung, together with a small
contribution of time constant inequalities at the peripheral airspaces
[34]. Lung static elastance (Est) was calculated by dividing Pel by
the tidal volume. ΔE was calculated as the difference between static
and dynamic elastances and reﬂects the viscoelastic component of
elastance.
2.9. Statistical analyses
All data are presented as the means ± standard error of the
means, and after testing normality by the Kolmogorov–Smirnov
test, the signiﬁcance of differences was analyzed by one-way
ANOVA followed by Tukey's post-hoc test, with p b 0.05. The unique
exception was the data from the inﬂammatory score, which was test-
ed by the Kruskal–Wallis test followed by Dunn's multiple compari-
son tests (p b 0.05). The software GraphPad Prism 5 was used for
statistical analysis (GraphPad Prism version 5.0, San Diego, CA, USA).
3. Results
3.1. Effects of statins on lung histology
Histological analysis was scored (Table 2) and revealed that con-
trol mice had intact alveolar septa and normal alveoli (Fig. 2). The
LPS group showed areas of alveolar septal edema, congestion and
Table 2
The effects of statins on the inﬂammatory scores of mouse lungs.
Groups Alveolar
congestion
Hemorrhage Inﬁltration of
leukocytes
Alveolar wall
thickness
Control 0 0 0.4 ± 0.16 0.2 ± 0.13
LPS 3.7 ± 0.33*** 2.6 ± 0.26*** 4.3 ± 0.15*** 2.9 ± 0.17***
A + LPS 0.5 ± 0.16### 0.9 ± 0.17# 1.0 ± 0.21### 0.9 ± 0.27##
P + LPS 0.8 ± 0.24## 1.1 ± 0.23 1.7 ± 0.21# 0.7 ± 0.21##
S + LPS 0.9 ± 0.23# 0.5 ± 0.16### 2.5 ± 0.34 1.8 ± 0.41
Acute lung injury was scored in ten ﬁelds from non-identiﬁed sections of each group
according to the following four criteria: alveolar congestion, hemorrhage, inﬁltration
of leukocytes in lung tissue, and thickness of the alveolar wall/hyaline membrane for-
mation. Each criterion was graded according to a 5-point scale: 0, minimal (little) dam-
age; 1, mild damage; 2, moderate damage; 3, severe damage; and 4, maximal damage.
The statistical analyses were performed with the Kruskal–Wallis test followed by
Dunn’s multiple comparison test, with a signiﬁcance level of 5%. *** p b 0.001 com-
pared with the control group. # p b 0.05, ## p b 0.01 and ### p b 0.001 when com-
pared with the LPS group.
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were observed in the alveoli (Fig. 2b). The A + LPS group showed
areas of alveolar septal edema, but to a lesser extent than the LPS
group, and some degree of bleeding without congestion and without
parenchymal collapse. Few inﬂammatory cells were observed in the
alveoli (Fig. 2c). The P + LPS group also showed areas of alveolarFig. 2. Lung parenchyma HE-stained images. a) control group with intact alveolar septa and
orrhage without parenchymal collapse; c) A + LPS with areas of alveolar septal edema an
group with areas of alveolar septal edema and some degree of bleeding, without congestion
edema compared to the LPS group and without hemorrhage, congestion or collapse of theseptal edema, again to a lesser extent than the LPS group, some de-
gree of bleeding, and no congestion or collapse of the parenchyma. In-
ﬂammatory cells were again observed in the alveoli (Fig. 2d). The
S + LPS group showed small areas of alveolar septal edema com-
pared to the LPS group but did not show hemorrhage, congestion or
collapse of the parenchyma. Few inﬂammatory cells were observed
in the alveoli (Fig. 2e). Among the groups treated with statins, the
most normal histology was observed in mice pretreated with prava-
statin followed by pretreatment with atorvastatin. The simvastatin
group, despite having a better histology than the LPS group, showed
the weakest protective effect.
3.2. The effects of statins on inﬂammatory markers
Inﬂammatory markers are shown in Table 3. Bronchoalveolar la-
vage was used to evaluate the alveolar leukocyte count as an inde-
pendent measure of alveolar inﬂammation. In animals injected with
LPS, total leukocytes increased 83% compared with control animals
(p b 0.01). Pre-treatment with pravastatin reduced the number of
leukocytes by 44% (p b 0.001), and pre-treatment with simvastatin
reduced the number of leukocytes by 39% (p b 0.05) compared to
the LPS group. We did not observe a signiﬁcant reduction in leukocyte
numbers in the group treated with atorvastatin. Polymorphonuclear
(PMN) and mononuclear (MN) cells in alveoli were counted in lungnormal alveoli; b) LPS group with areas of alveolar septal edema, congestion and hem-
d some degree of bleeding, without congestion and parenchymal collapse; d) P + LPS
and collapse of the parenchyma; e) S + LPS group with small areas of alveolar septal
parenchyma.
Table 3
The effects of statins on inﬂammatory markers.
Groups Control LPS A + LPS P + LPS S + LPS
Leukocytes (×105/mL) 3.40 ± 0.17 6.24 ± 0.65** 5.37 ± 0.49 3.52 ± 0.27## 3.85 ± 0.52#
MCP-1 (ng/mL) 0.26 ± 0.04 2.57 ± 0.39*** 1.80 ± 0.16 0.69 ± 0.09## 3.17 ± 0.45
MCP-1 mRNA (fold) 0.69 ± 0.21 2.12 ± 0.52** 0.88 ± 0.30## 1.22 ± 0.53 0.93 ± 0.43#
IL-6 (ng/mL) 5.47 ± 0.41 9.76 ± 1.27** 8.75 ± 0.44 5.10 ± 0.66## 5.86 ± 0.68#
IL-6 mRNA (fold) 0.56 ± 0.14 1.52 ± 0.21* 0.66 ± 0.23## 0.76 ± 0.12# 0.51 ± 0.16##
TNF-α (ng/mL) 6.01 ± 0.46 13.67 ± 0.95*** 8.86 ± 0.66## 7.27 ± 0.67### 6.04 ± 0.42###
TNF-α (fold) 0.52 ± 0.21 1.08 ± 0.21* 0.62 ± 0.33# 0.77 ± 0.24 0.87 ± 0.33
The data are expressed as the means ± SEM. MCP-1, IL-6 and TNF-α mRNA expression were examined, and the relative fold induction was normalized to a constitutive
gene (HPRT-1). The statistical analyses were performed using a one-way ANOVA followed by Tukey’s post-hoc test with a signiﬁcance level of 5%. * p b 0.05, ** p b 0.01 and
*** p b 0.001 compared with the control group. # p b 0.05, ## p b 0.01 and ### p b 0.001 when compared with the LPS group. ELISA was performed on BAL samples (n = 10).
qPCR was performed on lung homogenates (n = 5).
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the LPS group was 90% higher than that in the control group. The
number of MN cells was reduced in the P + LPS (52%) group com-
pared to the LPS group. The number of PMN cells in the LPS group
was 20 times higher than that in the control group (Fig. 3). The num-
ber of PMN cells was reduced in the A + LPS (24%), P + LPS (46%)
and S + LPS (31%) groups when compared with the LPS group.
When we examined the amount of MCP-1 in the lung after LPS treat-
ment, we observed an approximate 10-fold increase (p b 0.001),
while we observed an almost 2-fold increase for IL-6 and TNF-αFig. 3.Morphometrywas performed by countingmononuclear (MN) and polymorphonu-
clear (PMN) cells/ﬁeld in two different sections. Two investigators counted blinded sec-
tions. The number of MN cells in the LPS group was 90% higher than that in the control
group. The number of MN cells was reduced in the P + LPS (52%) group when compared
with the LPS group. The number of PMN cells in the LPS group was 20 times greater than
that in the control group. The number of PMN cells was reduced in the A + LPS (24%),
P + LPS (46%) and S + LPS (31%) groups when compared to the LPS group. The data
are expressed as the means ± SEM. The statistical analyses were performed by one way
ANOVA followed by Tukey’s post-hoc test, with a signiﬁcance level of 5%. *** p b 0.001
comparedwith the control group. # p b 0.05, ## p b 0.01 and###p b 0.001when com-
pared with the LPS group. (n = 5 per group).(p b 0.01 and p b 0.001, respectively) compared to the control
group. Pre-treatment with atorvastatin reduced the amount of
TNF-α by 34% (p b 0.01) compared to the LPS group. Pre-treatment
with pravastatin reduced the amount of MCP-1 by 74% (p b 0.01),
while the reductions observed for IL-6 and TNF-α were 48% (p b 0.01)
and 47% (p b 0.001), respectively, compared to the LPS group. Pre-
treatment with simvastatin reduced the amount of IL-6 and TNF-α by
41% (p b 0.05) and 55% (p b 0.001), respectively, compared to the LPS
group. MCP-1 gene expression increased 207% (p b 0.01), while IL-6
and TNF-α increased by 171% (p b 0.05) and two-fold (p b 0.05), re-
spectively, compared to the control group. Atorvastatin and simvastatin
show a 59% (p b 0.05) and 57% (p b 0.01) reduction in MCP-1 gene ex-
pression, respectively, when compared to LPS. Atorvastatin, pravastatin
and simvastatin also reduced the gene expression of IL-6 by 57%
(p b0.01), 50% (p b0.05) and 67% (p b 0.01), respectively, when com-
pared to LPS. Only atorvastatin reduced the expression of the TNF-α
gene by 42% (p b 0.05) when compared to LPS.
3.3. The effects of statins on redox markers
Redox markers are shown in Table 4. The activity of SOD increased
in the LPS group by 83% (p b 0.01) when compared to the control
group. Only treatment with atorvastatin signiﬁcantly reduced (40%,
p b 0.05) SOD activity compared to the LPS group. We observed an
approximately 7-fold (p b 0.01) increase in the expression of the su-
peroxide dismutase (SOD) gene in the group injected with LPS com-
pared to the control group. However, none of the statins reduced
the expression of SOD compared to the LPS group. The activity of
CAT increased in the LPS group by 60% (p b 0.001) compared to the
control group. Only pre-treatment with atorvastatin reduced (41%,
p b 0.01) CAT activity compared with LPS. With regard to catalase
(CAT) gene expression, we observed an increase of approximately
7-fold (p b 0.05) in the LPS group over the control group. Pre-
treatment with pravastatin and atorvastatin reduced CAT gene ex-
pression by 77% (p b 0.01) and 53% (p b 0.05), respectively, com-
pared to the LPS group. Malondialdehyde was increased by 80%
(p b 0.01) in the LPS group compared to the control group. Pre-
treatment with atorvastatin, pravastatin and simvastatin reduced
the levels of malondialdehyde by up to 41% (p b 0.05, p b 0.05 and
p b 0.01, respectively) compared with the LPS group. Hydroperoxide
levels increased in the LPS group by 81% (p b 0.01) compared with
the control group. Pre-treatment with atorvastatin, pravastatin and
simvastatin reduced these levels by up to 38% (p b 0.01, p b 0.05
and p b 0.01, respectively) compared with the LPS group. We also ob-
served an increase of 145% (p b 0.05) in the levels of protein carbon-
ylation for the LPS group compared to the control group. None of the
statins reduced protein carbonylation, although atorvastatin had a
tendency to decrease carbonylation (34%) compared to the LPS
group. The MPO activity in the BAL was used as a marker of acute
lung injury related to the accumulation of neutrophils. We observed
that mice injected with LPS showed an increase in MPO activity of
Table 4
Effects of statins on redox markers.
Groups Control LPS A + LPS P + LPS S + LPS
SOD (U/mg protein) 1.80 ± 0.11 3.34 ± 0.11** 2.04 ± 0.13## 3.27 ± 0.29 3.22 ± 0.25
SOD mRNA (fold) 0.80 ± 0.22 5.31 ± 0.39** 5.18 ± 1.51 4.30 ± 1.72 4.91 ± 1.46
CAT (U/mg protein) 7.81 ± 0.30 12.56 ± 0.67*** 7.48 ± 0.85## 11.54 ± 0.81 12.22 ± 0.81
CAT mRNA (fold) 0.16 ± 0.02 0.93 ± 0.47* 0.22 ± 0.06## 0.44 ± 0.15# 0.63 ± 0.18
MDA (nM/mg protein) 8.26 ± 0.96 14.87 ± 0.92** 10.12 ± 0.61# 9.70 ± 0.80# 8.83 ± 0.95##
LOOH (nM/mg protein) 0.027 ± 0.002 0.049 ± 0.004** 0.029 ± 0.002## 0.030 ± 0.002# 0.027 ± 0.001##
Carbonyl (nM/mg protein) 0.011 ± 0.001 0.027 ± 0.002* 0.018 ± 0.002 0.048 ± 0.007 0.052 ± 0.004
MPO (mU/mg protein) 6.43 ± 0.86 23.95 ± 3.09*** 18.85 ± 0.79 13.67 ± 0.99## 25.63 ± 1.89
Nitrite (mM/mg protein) 7.95 ± 0.94 12.94 ± 0.78* 14.83 ± 1.76 12.50 ± 0.95 18.70 ± 1.60
LDH (U/mg protein) 74.48 ± 29.98 301.80 ± 45.58** 187.70 ± 19.02 199.60 ± 35.78 357.55 ± 67.77
SOD, superoxide dismutase; CAT, catalase; MDA, malondialdehyde equivalents; LOOH, hydroperoxides; MPO, myeloperoxidase; LDH, lactate dehydrogenase. The data are expressed
as the means ± SEM. SOD and CAT mRNA expressions were examined, normalized and the relative fold induction was calculated to a constitutive gene (HRTP-1). The statistical
analyses were performed by one way ANOVA followed by Tukey's post-hoc test, with a signiﬁcance level of 5%. * p b 0.05, ** p b 0.01 and *** p b 0.001 compared with the control
group. # p b 0.05 and ## p b 0.01 when compared with the LPS group. MPO, nitrite and LDH were measured in BAL; other markers were measured in lung homogenates. N = 10
for all analyses except for qPCR, which was performed in lung homogenates with n = 5.
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with pravastatin reduced MPO activity by 44% (p b 0.01) compared
to the LPS group. There was no signiﬁcant difference in MPO activity
compared to the other statins. The amount of nitrite in the BAL was
analyzed here as an indirect indication of nitric oxide. We observed
a 63% increase (p b 0.05) in nitrite levels in the LPS group compared
to the control group. None of the statins reduced nitrite levels com-
pared with LPS. The activity of lactate dehydrogenase (LDH) was
higher (300%, p b 0.01) in the LPS group than in the control group.
However, none of the statins signiﬁcantly reduced the activity of
this enzyme, despite the fact that atorvastatin (35%) and pravastatin
(34%) presented a downward trend compared to the LPS group.
3.4. Effects of statins on pulmonary function
Respiratory function parameters were determined 24 hours after in-
jection of LPS or vehicle (Table 5). We observed that the LPS group
showed an increase in static elastance (p b 0.01), total airway resistance
(p b 0.05) and total pressure of the respiratory system (p b 0.05) com-
pared with the control group. Treatment with atorvastatin (p b 0.05)
and pravastatin (p b 0.01) reduced static elastance compared to the
LPS group, while pre-treatment with simvastatin had no effect. Total
airway resistance and total pressure of the respiratory system were not
altered by pre-treatment with statins compared to the LPS group,
although pre-treatment with atorvastatin and to a lesser extent with
pravastatin shows a tendency to decrease these parameters.
4. Discussion
Lipopolysaccharide is a constituent of the cell wall of gram nega-
tive bacteria, contributing to inﬂammation and systemic toxicity
[35]. Experimental models using endotoxins such as LPS have been
used to study acute lung injury [36]. Endotoxemia induced by intra-
peritoneal administration of LPS leads to lung injury and neutrophil
activation, and this situation causes free radical production [4].
The redox imbalance caused by an increase in free radicals and a
reduction in the antioxidant system may cause tissue damage [37].Table 5
Effects of statins on pulmonary function.
Groups Control LPS
Est,L (cm H2O/mL) 24.70 ± 1.62 34.56 ± 1.84**
Rtot,L-(cm H2O/mL) 0.67 ± 0.04 0.90 ± 0.04*
DPtot,L (cm H2O/mL) 0.65 ± 0.04 0.90 ± 0.04*
Est,L — static elastance; Rtot,L — total resistance of the airways; DPtot,L — total pressure o
analyses were performed by one way ANOVA followed by Tukey's post-hoc test, with a s
# p b 0.05 and ## p b 0.01 when compared with the LPS group. n = 5 for all.According to our study, statins possess pleiotropic effects beyond their
lipid-lowering properties, such as antioxidant and anti-inﬂammatory
activity.
In the present study, we observed an increase in leukocytes in the
bronchoalveolar lavage ﬂuid of the LPS group compared to the control,
and this increase was reduced by pre-treatment with pravastatin and
simvastatin but not atorvastatin. We also observed the increased levels
of MCP-1, IL-6 and TNF-α in the same groups. Pravastatin reduced the
levels of both MCP-1 and IL-6 but only induced changes in IL-6, while
not affecting MCP-1 or TNF-α expression. Simvastatin reduced the
levels of IL-6 and also reduced the gene expression of MCP-1 and IL-6;
these data are in concordance with Jacobson et al. [38]. Atorvastatin
did not cause changes in the levels of these cytokines but reduced
their expression, with the exception of TNF-α. Interestingly all statins
reduced TNF-α levels. Thus, statins exhibit anti-inﬂammatory actions,
possibly by inﬂuencing endothelial cells through the increased expres-
sion of β4 integrin [39], the inhibition of endothelial activation,
i.e., the inhibition of NFκB activation [40], the inhibition of ICAM-1
expression [41], or the inhibition of cytokine (IL-6) and chemokine
(MCP-1) production to prevent leukocyte adhesion to the endothe-
lium [42]. The increased gene expression of MCP-1 and IL-6 as well
as the increased levels of these inﬂammatory mediators are found
in acute coronary syndrome [43]. It should be noted that the key
hallmark of acute lung injury is damage to the blood barrier (pul-
monary vascular endothelium and alveolar basement membrane),
where neutrophils adhere to the wall of injured endothelium and
migrate into the airspace [44]. Pravastatin, which has microvascular
beneﬁts and anti-inﬂammatory effects, has been shown to reduce
leukocyte adhesion and macromolecular extravasation in the rat
mesentery 2–4 h after LPS-induced endotoxemia [45]. Pruefer and
coworkers published a paper demonstrating the effect of simvastatin
on the interaction between leukocytes and endothelial cells by intra-
vital microscopy in vivo. They concluded that simvastatin inhibited
leukocyte rolling, adhesion and transmigration in acute inﬂammato-
ry states and that this effect could be related to the downregulation
of P-selectin expression on endothelial cells [46]. We found no re-
duction in the level of BAL leukocytes in the atorvastatin-treatedA + LPS P + LPS S + LPS
26.11 ± 1.23# 23.46 ± 1.37## 33.12 ± 1.32
0.69 ± 0.06 0.80 ± 0.09 0.84 ± 0.06
0.69 ± 0.06 0.64 ± 0.08 0.91 ± 0.03
f the respiratory system. The data are expressed as the means ± SEM. The statistical
igniﬁcance level of 5%. * p b 0.05 and ** p b 0.01 compared with the control group.
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fewer polymorphonuclear cells in lung sections. In another study,
performed by Gaugler and colleagues with cultured endothelial cells
from the lungs of humans, pravastatin (1-1000 μM ﬁnal concentration)
was administered to limit the inﬂammatory response and endothelial
thrombosis after irradiation. The researchers observed an inhibition of
the excessive production of MCP-1, IL-6 and IL-8 [48]. Different families
of statins may have different biochemical functions even within the
same class, and there is a dose-response effect that can differentiate
the therapeutic potential of different statins [49]. One example is the
work of Iwata and colleagues, who used two types of statins, a lipophilic
(pitavastatin) and a hydrophilic (pravastatin) statin, and examined the
effects of these statins on cytokine production in human bronchial epi-
thelial cells stimulated by LPS [50]. The expression of IL-6 and IL-8 were
signiﬁcantly inhibited by both statins, and this inhibition was removed
when mevalonate was added, suggesting that their anti-inﬂammatory
effects may be connected to the mevalonic cascade. In a study of lung
injury due to ischemia and reperfusion, Wu and co-workers observed
damage to the alveolar cell type II and consequently impaired lung
repair of alveolar cell transdifferentiation in alveolar cell type I. They
used in vitro human ATII (A549) and mouse (MLE-12) cells, which
were subjected to hypoxia and re-oxygenation. Pre-treatment with
simvastatin reduced the apoptosis of these cells and the increased pro-
liferation and expression of surfactant proteins. In the experimental
model of ischemia/reperfusion, rats were treated with simvastatin and
also showed increased proliferation of ATII cells in vivo [2]. Finally, a
recent study fromWu and co-workers investigated the effect of simva-
statin in vitro on alveolar macrophages from human volunteers. The
cells were incubated with lipoteichoic acid, a component of the cell
wall of gram-positive bacteria (Staphylococcus aureus) and treated
with simvastatin. The results showed that ATL induced a potent pro-
inﬂammatory and pro-apoptotic state, and simvastatin exerted anti-
inﬂammatory effects by mediating the inhibition of NFκB activation
and cytokine expression in human alveolar macrophages [3].
Weobserved increasedMPO in the LPS group compared to the control
group. This ﬁnding suggests that the observed accumulation of leuko-
cytes in BAL ﬂuid was most likely derived primarily from neutrophils.
In support of this hypothesis, Suda et al. found abundant BAL neutrophils
after endotoxin-induced acute lung injury [51]. Pre-treatment with prav-
astatin caused a signiﬁcant reduction of MPO. A previous study reported
the protective effects of pravastatin in acute lung injury induced by LPS
with effects similar to those observed here. The group treated with prav-
astatin showed a signiﬁcant reduction not only in lung vascular leakage
induced by LPS but also in cellular inﬁltration in the lung tissue, including
a reduction in MPO activity [52]. In our study, we did not observe any
change in thismarker fromprior administration of atorvastatin or simva-
statin. Contrasting results were observed by Grommes et al. [53] with
respect to the simvastatin treatment, which may be explained by the
duration of treatment and the administration route.
Leukocyte activation can increase the production and release of free
radicals, causing redox imbalance in the lung. If the antioxidant system
of the lung does not provide adequate protection, oxidative stress con-
ditions occur with possible damage to tissues. Thus, we investigated the
activity and expression of the antioxidant enzymes SOD and CAT aswell
asmarkers of oxidative damage (malondialdehyde, carbonyl, hydroper-
oxides and lactate dehydrogenase) in lung homogenate. The group that
was stimulated with LPS showed increased expression of SOD and CAT.
No difference in SOD gene expression was observed in groups treated
with statins. However, we observed a reduction in CAT in groups treat-
ed with atorvastatin or pravastatin but not simvastatin. All statins re-
duced MDA levels (marker of lipid peroxidation) with simvastatin
having the strongest activity; these data are in accordance with those
of Altintas et al. [54]. Only the group treatedwith atorvastatin exhibited
decreased SOD and CAT activity aswell as reduced oxidative damage, as
determined by hydroperoxide levels. None of the statins reduced lactate
dehydrogenase levels, perhaps because this enzyme has an extremelyshort half-life. Finally, nitrite was not altered with any statin treatment
compared to the LPS group. Thus, the pharmacological properties of
each statin may produce different antioxidant activities. The duration
of pretreatment can also affect each drug’s antioxidant properties. We
suggest that the oxidative stress observed in this study is partially due
to the increased number of leukocytes in the LPS group. Therefore, a re-
duction in leukocytes could directly cause a reduction in redoxmarkers.
A survey of 114 patients with dyslipidemia who were treated with
statins was performed to evaluate the activities of antioxidant enzymes
(CAT, SOD and GPx) in erythrocytes. After treatment, which lasted from
4 to 12 weeks, there was a signiﬁcant increase in antioxidant enzyme
activity in patients who received atorvastatin and simvastatin. Therapy
with pravastatin only impacted CAT activity; there were no effects on
GPx and SOD [55]. We did not observe the same results in our study:
only the group receiving atorvastatin showed a decrease in the activity
of these enzymes when compared with LPS.
Endotoxin-induced LPA is associated with changes in respiratory
function, indicated by reduced dynamic compliance and increased
lung resistance. Mechanical changes have been attributed to pulmo-
nary edema followed by a deﬁcit in gas exchange and airway constric-
tion [56]. Our ﬁndings show that the groups treated with pravastatin
and atorvastatin reduced lung elasticity compared to the LPS group,
and there was a trend toward a reduction in airway resistance in
the atorvastatin group and in respiratory system pressure for the
pravastatin group. No positive results were observed with simvastatin.
Interestingly, a previous report in patients pre-treated with simvastatin
with acute lung injury and under mechanical ventilation did not show
any effect on pulmonary function [57].
The pravastatin group achieved better results than the atorvastatin
groupwith regard to inﬂammationmarkers (leukocyte counts, the pro-
duction ofMCP-1, IL-6 andmyeloperoxidase). Moreover, the histopath-
ological proﬁle with pravastatin was better than the atorvastatin group
when both were compared to LPS. In this study, we found that atorva-
statin exhibited the best results in terms of enhanced antioxidant en-
zyme (SOD and CAT) activity in addition to a reduction in markers
of oxidative damage (MDA and hydroperoxide). We suggest that the
mechanism by which atorvastatin can inﬂuence lung elasticity is by
reducing alveolar edema, given atorvastatin's capacity to act as an anti-
oxidant, but more research is needed to strengthen this suggestion. The
differences between classes of statins and their pharmacokinetic char-
acteristics, such as liver metabolism and half-life associated with the
dose and duration of drug use, are features that should be taken into
account in future studies.
In this study, we used 3 different statins: atorvastatin, which is li-
pophilic and synthetic; pravastatin, which is hydrophilic and fermen-
tation derived and simvastatin, which is lipophilic and fermentation
derived. Neither the lipophilicity nor the origin of the statins was as-
sociated with oxidative stress or the reduction of inﬂammation in the
acute lung injury groups.
In conclusion, we suggest, after histological, biochemical and func-
tional analysis of our endotoxin-induced acute lung injury model,
that pravastatin is the best anti-inﬂammatory therapy, while atorva-
statin is the best antioxidant therapy. Simvastatin showed the least
pleiotropic activities.
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